المؤلفون: Maartje W. Rohaan, Troels H. Borch, Joost H. van den Berg, Özcan Met, Rob Kessels, Marnix H. Geukes Foppen, Joachim Stoltenborg Granhøj, Bastiaan Nuijen, Cynthia Nijenhuis, Inge Jedema, Maaike van Zon, Saskia Scheij, Jos H. Beijnen, Marten Hansen, Carlijn Voermans, Inge M. Noringriis, Tine J. Monberg, Rikke B. Holmstroem, Lidwina D.V. Wever, Marloes van Dijk, Lindsay G. Grijpink-Ongering, Ludy H.M. Valkenet, Alejandro Torres Acosta, Matthias Karger, Jessica S.W. Borgers, Renske M.T. ten Ham, Valesca P. Retèl, Wim H. van Harten, Ferry Lalezari, Harm van Tinteren, Astrid A.M. van der Veldt, Geke A.P. Hospers, Marion A.M. Stevense-den Boer, Karijn P.M. Suijkerbuijk, Maureen J.B. Aarts, Djura Piersma, Alfons J.M. van den Eertwegh, Jan-Willem B. de Groot, Gerard Vreugdenhil, Ellen Kapiteijn, Marye J. Boers-Sonderen, W. Edward Fiets, Franchette W.P.J. van den Berkmortel, Eva Ellebaek, Lisbet R. Hölmich, Alexander C.J. van Akkooi, Winan J. van Houdt, Michel W.J.M. Wouters, Johannes V. van Thienen, Christian U. Blank, Aafke Meerveld-Eggink, Sebastian Klobuch, Sofie Wilgenhof, Ton N. Schumacher, Marco Donia, Inge Marie Svane, John B.A.G. Haanen

المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Biochemistry, CCA - Cancer Treatment and Quality of Life, AII - Cancer immunology, Landsteiner Laboratory, General Internal Medicine, Health Technology & Services Research, Health Technology Assessment (HTA), Medical Oncology, Erasmus MC other, Surgery, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOC
The New England Journal of Medicine, 387, 2113-2125
New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
Rohaan, M W, Borch, T H, Van Den Berg, J H, Met, Ö, Kessels, R, Geukes Foppen, M H, Stoltenborg Granhøj, J, Nuijen, B, Nijenhuis, C, Jedema, I, Van Zon, M, Scheij, S, Beijnen, J H, Hansen, M, Voermans, C, Noringriis, I M, Monberg, T J, Holmstroem, R B, Wever, L D V, Van Dijk, M, Grijpink-Ongering, L G, Valkenet, L H M, Torres Acosta, A, Karger, M, Borgers, J S W, Ten Ham, R M T, Retèl, V P, Van Harten, W H, Lalezari, F, Van Tinteren, H, Van Der Veldt, A A M, Hospers, G A P, Stevense-Den Boer, M A M, Suijkerbuijk, K P M, Aarts, M J B, Piersma, D, Van Den Eertwegh, A J M, De Groot, J W B, Vreugdenhil, G, Kapiteijn, E, Boers-Sonderen, M J, Fiets, W E, Van Den Berkmortel, F W P J, Ellebaek, E, Hölmich, L R, Van Akkooi, A C J, Van Houdt, W J, Wouters, M W J M, Van Thienen, J V, Blank, C U, Meerveld-Eggink, A, Klobuch, S, Wilgenhof, S, Schumacher, T N, Donia, M, Svane, I M & Haanen, J B A G 2022, ' Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. ', New England Journal of Medicine, vol. 387, no. 23, pp. 2113-2125 . https://doi.org/10.1056/NEJMoa2210233Test
The New England journal of medicine, 387(23), 2113-2125. Massachussetts Medical Society
New England Journal of Medicine, 387(23), 2113-2125. MASSACHUSETTS MEDICAL SOCIETY
The New England Journal of Medicine, 387, 23, pp. 2113-2125

مصطلحات موضوعية: Adoptive, Cell- and Tissue-Based Therapy, Outcomes, Dermatology, Metastatic melanoma, Guidelines, Immunotherapy, Adoptive, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Lymphocytes, Tumor-Infiltrating, SDG 3 - Good Health and Well-being, Adoption, Humans, Melanoma/drug therapy, Lymphocytes, Tumor-Infiltrating, Melanoma, Skin Cancer, Treatments in Oncology, Cancer, General Medicine, Complete responses, Hematology/Oncology, Ipilimumab, n/a OA procedure, Adoptive cell therapy, Nivolumab, Ipilimumab/adverse effects, Immunotherapy

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edf28a71e5a16116e2b0f59cdac9485aTest
https://research.rug.nl/en/publications/9033fdbd-9e6f-4cca-a35b-50890da9f292Test

المؤلفون: Patricio Serra-Bellver, Judith M. Versluis, Honey K. Oberoi, Cong Zhou, Timothy D. Slattery, Yasir Khan, James R. Patrinely, Inês Pires da Silva, C. Martínez-Vila, Natalie Cook, Donna M. Graham, Matteo S. Carlino, Alexander M. Menzies, Ana M. Arance, Douglas B. Johnson, Georgina V. Long, Lisa Pickering, James M.G. Larkin, Christian U. Blank, Paul Lorigan

المصدر: European Journal of Cancer. 176:121-132

مصطلحات موضوعية: History, Cancer Research, Nivolumab, Polymers and Plastics, Oncology, Brain Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Business and International Management, Ipilimumab, Melanoma, Industrial and Manufacturing Engineering, Retrospective Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc088fa3fd7d252dd7cf0be202702801Test
https://doi.org/10.1016/j.ejca.2022.09.004Test

المؤلفون: Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jesper van Breeschoten, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk

المساهمون: Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: European journal of cancer (Oxford, England : 1990), 167, 70-80. Elsevier Ltd.
van Not, O J, de Meza, M M, van den Eertwegh, A J M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, van Breeschoten, J, de Groot, J-W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Bonenkamp, H J, Boers-Sonderen, M J, Blokx, W A M, Wouters, M W J M & Suijkerbuijk, K P M 2022, ' Response to immune checkpoint inhibitors in acral melanoma : A nationwide cohort study ', European Journal of Cancer, vol. 167, pp. 70-80 . https://doi.org/10.1016/j.ejca.2022.02.026Test
European Journal of Cancer, 167, 70-80. ELSEVIER SCI LTD
European Journal of Cancer, 167, pp. 70-80
European Journal of Cancer, 167, 70-80
European Journal of Cancer, 167, 70-80. Pergamon

مصطلحات موضوعية: Cancer Research, Skin Neoplasms, Survival, Melanoma/mortality, THERAPY, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], SUBTYPES, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Immune checkpoint inhibitors, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Skin Neoplasms/drug therapy, Humans, Prospective Studies, Melanoma, OUTCOMES, Response, KIT, EFFICACY, Nivolumab/adverse effects, Ipilimumab, Immune Checkpoint Inhibitors/therapeutic use, MUCOSAL, Nivolumab, Oncology, ARM, Immunotherapy, Ipilimumab/therapeutic use

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e0333d1ed14f8c5e0b759f512b98e9Test
http://www.scopus.com/inward/record.url?scp=85127559750&partnerID=8YFLogxKTest

المؤلفون: Inês Pires da Silva, Tasnia Ahmed, Jennifer L. McQuade, Caroline A. Nebhan, John J. Park, Judith M. Versluis, Patricio Serra-Bellver, Yasir Khan, Tim Slattery, Honey K. Oberoi, Selma Ugurel, Lauren E. Haydu, Rudolf Herbst, Jochen Utikal, Claudia Pföhler, Patrick Terheyden, Michael Weichenthal, Ralf Gutzmer, Peter Mohr, Rajat Rai, Jessica L. Smith, Richard A. Scolyer, Ana M. Arance, Lisa Pickering, James Larkin, Paul Lorigan, Christian U. Blank, Dirk Schadendorf, Michael A. Davies, Matteo S. Carlino, Douglas B. Johnson, Georgina V. Long, Serigne N. Lo, Alexander M. Menzies

المصدر: Pires da Silva, I, Ahmed, T, McQuade, J L, Nebhan, C A, Park, J J, Versluis, J M, Serra-Bellver, P, Khan, Y, Slattery, T, Oberoi, H K, Ugurel, S, Haydu, L E, Herbst, R, Utikal, J, Pföhler, C, Terheyden, P, Weichenthal, M, Gutzmer, R, Mohr, P, Rai, R, Smith, J L, Scolyer, R A, Arance, A M, Pickering, L, Larkin, J, Lorigan, P, Blank, C U, Schadendorf, D, Davies, M A, Carlino, M S, Johnson, D B, Long, G V, Lo, S N & Menzies, A M 2022, ' Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 10, pp. 1068-1080 . https://doi.org/10.1200/JCO.21.01701Test

مصطلحات موضوعية: Cancer Research, Lung Neoplasms, Manchester Cancer Research Centre, Oncology, ResearchInstitutes_Networks_Beacons/mcrc, Medizin, Humans, Neoplasms, Second Primary, Immunotherapy, Ipilimumab, Melanoma, Progression-Free Survival

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e76065c510604a83b0805fd88f0ad2d7Test
https://doi.org/10.1200/jco.21.01701Test

المؤلفون: Bart Neyns, Christian U. Blank, Michal Lotem, Mark R. Middleton, J.-J. Grob, Melanie A. Leiby, Antoni Ribas, C. Robert, Jacob Schachter, Céleste Lebbé, Euan Walpole, Matteo S. Carlino, Neil Steven, Nageatte Ibrahim, Peter Mohr, A. Arance, Paul Lorigan, Mario Sznol, Erin Jensen, Georgina V. Long, Laurent Mortier

المساهمون: Faculty of Law and Criminology, Medical Oncology, Clinical sciences, Laboratory of Molecular and Medical Oncology, Faculty of Arts and Philosophy

المصدر: Long, G V, Arance, A, Mortier, L, Lorigan, P, Blank, C, Mohr, P, Schachter, J, Grob, J-J, Lotem, M, Middleton, M R, Neyns, B, Steven, N, Ribas, A, Walpole, E, Carlino, M S, Lebbe, C, Sznol, M, Jensen, E, Leiby, M A, Ibrahim, N & Robert, C 2022, ' Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma : analysis from KEYNOTE-006 ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 33, no. 2, pp. 204-215 . https://doi.org/10.1016/j.annonc.2021.10.010Test

مصطلحات موضوعية: Proto-Oncogene Proteins B-raf, advanced melanoma, Oncology, BRAF inhibition, medicine.medical_specialty, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Internal medicine, medicine, Humans, In patient, ipilimumab, Melanoma, Complete response, Advanced melanoma, Mitogen-Activated Protein Kinase Kinases, Antitumor activity, Manchester Cancer Research Centre, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, Hematology, medicine.disease, MEK inhibition, pembrolizumab, business, Progressive disease, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ae40264769d12ae7ca2fde50f109b8fTest
https://doi.org/10.1016/j.annonc.2021.10.010Test

المؤلفون: Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi, Judith M. Versluis, Noëlle M. J. van den Heuvel, Robyn P. M. Saw, Thomas E. Pennington, Ellen Kapiteijn, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Geke A. P. Hospers, Elisa A. Rozeman, Willem M. C. Klop, Winan J. van Houdt, Karolina Sikorska, Jos A. van der Hage, Dirk J. Grünhagen, Michel W. Wouters, Arjen J. Witkamp, Charlotte L. Zuur, Judith M. Lijnsvelt, Alejandro Torres Acosta, Lindsay G. Grijpink-Ongering, Maria Gonzalez, Katarzyna Jóźwiak, Carolien Bierman, Kerwin F. Shannon, Sydney Ch’ng, Andrew J. Colebatch, Andrew J. Spillane, John B. A. G. Haanen, Robert V. Rawson, Bart A. van de Wiel, Lonneke V. van de Poll-Franse, Richard A. Scolyer, Annelies H. Boekhout, Georgina V. Long, Christian U. Blank

المساهمون: Medical and Clinical Psychology, Oral and Maxillofacial Surgery, Medical Oncology, Radiology & Nuclear Medicine, Surgery, Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: Nature Medicine, 28(6), 1178-+. NATURE PORTFOLIO
Nature Medicine, 28(6), 1178-1188. Nature Publishing Group
Nature Medicine
Nature medicine, 28(6), 1178-1188. Nature Publishing Group
Nature Medicine, 28. Nature Publishing Group

مصطلحات موضوعية: Skin Neoplasms, General Medicine, BIOMARKER ANALYSES, Ipilimumab, Neoadjuvant Therapy, General Biochemistry, Genetics and Molecular Biology, MORBIDITY, Nivolumab, QUALITY-OF-LIFE, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, BIOPSY, SURVIVAL, Humans, AXILLARY, Neoplasm Recurrence, Local, IMMUNOTHERAPY, Melanoma, DISSECTION, SENTINEL LYMPH-NODE, Neoplasm Staging

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67d79d3cfe1f3c168f561afa30efdc6cTest
https://doi.org/10.1038/s41591-022-01851-xTest

المؤلفون: Olivier J. van Not, Rik J. Verheijden, Alfonsus J. M. van den Eertwegh, John B. A. G. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Jan-Willem B. de Groot, Geke A. P. Hospers, Anna M. Kamphuis, Ellen Kapiteijn, Anne M. May, Melissa M. de Meza, Djura Piersma, Rozemarijn van Rijn, Marion A. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Willeke A. M. Blokx, Michel J. M. Wouters, Karijn P. M. Suijkerbuijk

المساهمون: Medical Oncology, Radiology & Nuclear Medicine, Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), Guided Treatment in Optimal Selected Cancer Patients (GUTS)

المصدر: JAMA Oncology. AMER MEDICAL ASSOC
JAMA Oncology
JAMA Oncology, 8(12), 1794-1801. American Medical Association
van Not, O J, Verheijden, R J, van den Eertwegh, A J M, Haanen, J B A G, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, de Groot, J-W B, Hospers, G A P, Kamphuis, A M, Kapiteijn, E, May, A M, de Meza, M M, Piersma, D, van Rijn, R, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Blokx, W A M, Wouters, M J M & Suijkerbuijk, K P M 2022, ' Association of Immune-Related Adverse Event Management with Survival in Patients with Advanced Melanoma ', JAMA Oncology, vol. 8, no. 12, pp. 1794-1801 . https://doi.org/10.1001/jamaoncol.2022.5041Test
JAMA oncology, 8(12), 1794-1801. AMER MEDICAL ASSOC
Jama Oncology, 8, 12, pp. 1794-1801
Jama Oncology, 8, 1794-1801

مصطلحات موضوعية: Male, Cancer Research, IPILIMUMAB, NIVOLUMAB, Middle Aged, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Cohort Studies, Immune System Diseases, Oncology, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Humans, FAILURE, Female, Steroids, Melanoma, Immunosuppressive Agents, Retrospective Studies, ANTI-TNF

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b26478643297b0e2ad8b55899ada18aTest
http://hdl.handle.net/1887/3564012Test

المؤلفون: Céleste Lebbé, Ines Pires da Silva, Irene L.M. Reijers, Megan Lyle, Alexander M. Menzies, Alison Weppler, Shahneen Sandhu, Camille L. Gerard, Matteo S. Carlino, Joanna Mangana, Douglas B. Johnson, Patricio Serra-Bellver, Oliver Klein, James R. Patrinely, Andrew Haydon, Tasnia Ahmed, Olivier Michielin, Khang Nguyen, Claudia Trojaniello, Paul Lorigan, Allison Betof Warner, Dan Stout, Clara Allayous, Christian U. Blank, Paolo A. Ascierto, Lisa Zimmer, Serigne Lo, Georgina V. Long

المصدر: The Lancet Oncology. 22:836-847

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, Pembrolizumab, Antibodies, Monoclonal, Humanized, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, Positron Emission Tomography Computed Tomography, Internal medicine, medicine, Clinical endpoint, Humans, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Immune Checkpoint Inhibitors, Melanoma, Aged, Retrospective Studies, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Progression-Free Survival, Nivolumab, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9178dd6e7066c6eafdc578a3589333b7Test
https://doi.org/10.1016/s1470-2045Test(21)00097-8

المؤلفون: Prachi Bhave, Tasnia Ahmed, Serigne N Lo, Alexander Shoushtari, Anne Zaremba, Judith M Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K Schwarze, Meghan J Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U Blank, Egle Ramelyte, Katharina C Kähler, Severine Roy, Paolo A Ascierto, Olivier Michielin, Paul C Lorigan, Douglas B Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A McArthur, Andrew M Haydon, Georgina V Long, Alexander M Menzies, Matteo S Carlino

المساهمون: Clinical sciences, Laboratory of Molecular and Medical Oncology, Internal Medicine, Faculty of Medicine and Pharmacy, Medical Oncology

المصدر: Bhave, P, Ahmed, T, Lo, S N, Shoushtari, A, Zaremba, A, Versluis, J M, Mangana, J, Weichenthal, M, Si, L, Lesimple, T, Robert, C, Trojanello, C, Wicky, A, Heywood, R, Tran, L, Batty, K, Dimitriou, F, Stansfeld, A, Allayous, C, Schwarze, J K, Mooradian, M J, Klein, O, Mehmi, I, Roberts-Thomson, R, Maurichi, A, Yeoh, H L, Khattak, A, Zimmer, L, Blank, C U, Ramelyte, E, Kähler, K C, Roy, S, Ascierto, P A, Michielin, O, Lorigan, P C, Johnson, D B, Plummer, R, Lebbe, C, Neyns, B, Sullivan, R, Hamid, O, Santinami, M, McArthur, G A, Haydon, A M, Long, G V, Menzies, A M & Carlino, M S 2022, ' Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma ', Journal for ImmunoTherapy of Cancer, vol. 10, no. 7, e004668 . https://doi.org/10.1136/jitc-2022-004668Test

مصطلحات موضوعية: Pharmacology, Cancer Research, Skin Neoplasms, Manchester Cancer Research Centre, ResearchInstitutes_Networks_Beacons/mcrc, Immunology, Programmed Cell Death 1 Receptor, Medizin, Ipilimumab, oncology, Molecular Medicine, Immunology and Allergy, Humans, CTLA-4 Antigen, Immunotherapy, immunotherapy, Prospective Studies, Melanoma, Retrospective Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b5a9d00012b0583c371b3485e31ff2Test
https://pubmed.ncbi.nlm.nih.gov/35793872Test

المؤلفون: Alfonsus J. M. van den Eertwegh, Michel W.J.M. Wouters, Roos S. van Rijn, John B. A. G. Haanen, Maureen J.B. Aarts, Bert-Jan J. ten Tije, Karijn P M Suijkerbuijk, Christian U. Blank, Jesper van Breeschoten, Geke A. P. Hospers, Jan-Willem B de Groot, Franchette W P J van den Berkmortel, Ellen Kapiteijn, Doranne L. Hilarius, Marye J Boers-Sonderen, Djura Piersma, Art Vreugdenhil, Astrid A M van der Veldt, Willeke A. M. Blokx

المساهمون: VU University medical center, Obstetrics and gynaecology, Internal medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9)

المصدر: British Journal of Cancer
British Journal of Cancer, 124(7), 1222-1230. Nature Publishing Group
British Journal of Cancer, 124, 7, pp. 1222-1230
British Journal of Cancer, 124, 1222-1230
van Breeschoten, J, Wouters, M W J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, Blokx, W A M, Tije, B-J J T, Veldt, A A M V D, Vreugdenhil, A, Boers-Sonderen, M J & van den Eertwegh, A J M 2021, ' First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis ', British Journal of Cancer, vol. 124, no. 7, pp. 1222-1230 . https://doi.org/10.1038/s41416-020-01229-1Test
British Journal of Cancer, 124(7), 1222-1230. SPRINGERNATURE

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, PHASE-3, First line, Systemic therapy, VEMURAFENIB, Article, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], POOLED ANALYSIS, Matched cohort, SDG 3 - Good Health and Well-being, Internal medicine, Medicine, METASTATIC MELANOMA, neoplasms, Melanoma, Survival analysis, Advanced melanoma, nivolumab, business.industry, IPILIMUMAB, Anti pd 1, medicine.disease, DABRAFENIB, Propensity score matching, pembrolizumab, business

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::836391be4c5b8d33487fc86cac6f6337Test
https://doi.org/10.1038/s41416-020-01229-1Test